Characterization of pulmonary venous hypertension patients with reactive pulmonary hypertension as compared to proportional pulmonary hypertension

Respiration

Volumn 83, Issue 6, 2012, Pages 494-498

  Berger, Gidon ^a,b,d   Hardak, Emilia ^a,d   Obaid, Waleed ^d   Shaham, Beatrice ^a   Carasso, Shemi ^c   Kerner, Arthur ^c   Yigla, Mordechai ^a,d   Azzam, Zaher S ^b,d  

^a Division of Pulmonary Medicine   (Israel)

^b Israel Institute of Technology ^*  (Israel)

^c Heart Institute   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Pulmonary capillary wedge pressure; Pulmonary hypertension; Pulmonary vascular resistance; Pulmonary venous hypertension; Right heart catheterization; Transpulmonary gradient

Indexed keywords

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; HIGH RISK PATIENT; HUMAN; LUNG VEIN HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REACTIVE PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; FEMALE; HEART CATHETERIZATION; HEART DISEASES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY HEART DISEASE; PULMONARY WEDGE PRESSURE; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 84862764033     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000329446     Document Type: Article

References (15)

1. Simonneau G, Robbins I, Beghetti M, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54(suppl 1):S43-S54.
2. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton M, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr 2005; 18: 1440-1463.
3. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107-133.
4. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-193.
5. Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN, Zhao DX, Byrne DW: Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009; 136: 31-36.
6. Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM: Pulmonary hypertension in heart failure with preserved ejection fraction: a communitybased study. J Am Coll Cardiol 2009; 53: 1119-1126.
7. Mathier MA: Pulmonary hypertension in heart failure. Medscape Pulmonary Medicine 2008 .
8. Butler J, Chomsky DB, Wilson JR: Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999; 34: 1802-1806.
9. Kraemer MD, Kubo SH, Rector TS, Brunsvold N, Bank AJ: Pulmonary and peripheral vascular factors are important determinants of peak exercise oxygen uptake in patients with heart failure. J Am Coll Cardiol 1993; 21: 641-648.
10. Neuman Y, Kotliroff A, Bental T, Siegel R, David D, Lishner M: Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol 2008; 127: 174-178.
11. Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure. The role of the endothelium in pathophysiology and management. Circulation 2000; 102: 1718.
12. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
13. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL: Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11: 12-20.
14. Kalra PR, Moon JC, Coats AJ: Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195-197.
15. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ: Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555-1562.